Navigation Links
JDRF award supports study of potential target for blocking type 1 diabetes
Date:9/2/2009

NORFOLK, Va. Scientists at Eastern Virginia Medical School's Strelitz Diabetes Center have been awarded a two-year grant totaling $472,683 by the Juvenile Diabetes Research Foundation (JDRF).

The center's research team, led by Jerry Nadler, MD, professor and chair of internal medicine and director of the center, has been studying the role of an enzyme called 12- Lipoxygenase (12-LO) in damaging insulin-producing beta cells, a condition that leads to Type 1 Diabetes. "We have successfully identified a vital step in the development of Type 1 diabetes and we are hopeful that blocking this enzyme could hold the key to engineering breakthrough new treatments," Dr. Nadler said.

12-LO is a protein-based enzyme in beta cells that produces lipids. These lipids are highly pro-inflammatory and can lead to the death of beta cells. EVMS researchers have demonstrated that deletion of the gene that produces 12-LO in animal models prevents the development of Type 1 Diabetes at a rate of nearly 100 percent.

The group has now identified the particular form of 12-LO found in human insulin producing cells. And, while still preliminary, this research could help scientists develop a novel therapeutic approach to stop beta cells from being destroyed and to allow functional regeneration of beta cells in Type 1 Diabetes patients. Working with Ted Holman, PhD, a professor of chemistry and biochemistry at the University of California, Santa Cruz, the EVMS team hopes to use these findings to help develop a new drug.

"We are fortunate to be working with Dr. Holman, who has discovered some very promising compounds that can reduce 12-LO activity. Now, with the generosity and support of the JDRF, we can apply this technology to help prevent the destruction of beta cells and allow the regeneration of insulin-producing cells in Type 1 Diabetes," Dr. Nadler said.

"Dr. Nadler and his team have made amazing strides in our understanding of how lipoxygenase may contribute to the development of diabetes and opens the possibility of directly targeting this enzyme for treatment," Dr. Holman said. "Based on this important discovery, Dr. Nadler has already begun testing our lipoxygenase inhibitors in the hopes of generating new treatments for diabetes. His preliminary results are very promising and with his recent funding by the JDRF, we hope to make further progress."

"JDRF is thrilled to be supporting Dr. Nadler's work at EVMS as this research may represent an important step toward the development of a new therapeutic strategy for treating type 1 diabetes," said Patricia Kilian, PhD, director of regeneration at JDRF.

Often diagnosed in children and young adults, Type 1 diabetes, previously known as juvenile diabetes, is an autoimmune disorder associated with the destruction of insulin-producing beta cells. Without insulin, the body is unable to process sugars and starches leaving it unable to convert them into energy for movement, growth, repair and other functions.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-6074
Eastern Virginia Medical School
Source:Eurekalert

Related medicine news :

1. ING Awards $100,000 in Grants to Combat Childhood Obesity
2. Empire Blue Cross Blue Shield Awarded NCQAs Accreditation Status of Excellent
3. Regence Foundation Awards Nearly $250,000 in Grants to Northwest Nonprofits
4. Vigilan Earns Honor in the 2009 Product & Technology Awards Program by Mature Market Resource Center
5. American Chemical Society Awards John R. Engen for Scientific Achievements
6. Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award
7. Nielsen Announces Final Entry Deadline Extension of September 10th for the First-Ever CLIO Healthcare Awards
8. Rhode Island Hospital awarded $11 million, 5-year renewal
9. Lundbeck Inc. Recognized With Award of Excellence in Corporate Achievement for Its Commitment to Huntingtons Disease Community
10. Sundia Receives the Highest Growth Potential Award from Zhangjiang
11. The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... ... March 01, 2017 , ... Today, True Vision Funding LLC ... formation of a new division for the purchase of sports and music entertainment ... , Clinton Portis, former Washington Redskins running back and supporter for TVF ...
(Date:3/1/2017)... ... March 01, 2017 , ... Financial Recovery Group, Inc. (FRG), is ... Nashville Summit in Nashville, Tenn. The company also is offering a special discount for ... in its 11th year, brings together the brightest minds in the healthcare industry to ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... pleased to announce the release of its 2017 update to Compass, the ... staff and physician advisors. , Suitable for standardizing both new-hire on-boarding and ...
(Date:3/1/2017)... ANGELES, CA (PRWEB) , ... March 01, 2017 , ... ... launch of her new mobile app Time & Go. , Time & Go app ... of life: career, relationships, and well-being. Efficient time management methods enable people to work ...
(Date:3/1/2017)... ... March 01, 2017 , ... “There is Comfort for the Soul”: ... the author in their all-too-brief time together, and the soul-healing comfort provided by God’s ... the creation of published author, Jerie A. Tau, a dog-loving medical professional whose work ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... 1, 2017  Global biotherapeutics leader CSL Behring ... ever Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) trial, known as ... reatment with H izentra ® ).  The Phase ... safety and tolerability of two different doses of CSL ... Subcutaneous [Human]), compared with placebo, in the maintenance treatment ...
(Date:3/1/2017)... 1, 2017  The Pharmaceutical Care Management Association (PCMA) ... vote to advance the nomination of Seema Verma ... Services Administrator: "The popular Medicare Part ... American health care. By offering an abundance of competing ... tools like pharmacy networks and home delivery, the program ...
(Date:3/1/2017)... -- The global  Intraoperative Neuromonitoring (IONM) market  is expected to reach ... Research, Inc. The intraoperative neuromonitoring market is anticipated to witness significant growth in ... in a wide spectrum of surgeries. Continue Reading ... ... ...
Breaking Medicine Technology: